Active, not recruitingPhase 4

The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression

NCT07179913 · esketamine · The First Hospital of Jilin University

Closed to entry

Status

Not accepting participants

Phase 4

Phase

Target enrolment

Study sites

Outside the US

What it is testing

Summary

The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infusion and the addition of a small dose of esketamine to the postoperative analgesic pump can help reduce the proportion of patients with depression after surgery, and may further improve postoperative recovery, reduce the use of postoperative opioids, shorten postoperative hospital stay, and improve postoperative quality of life of patients.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Hamilton Depression Scale ≥7
Measured over Seven days after the operation

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion Criteria: * Age ≥18 years old and \<65 years old * Patients with a BMI greater than 35 kg/m\^2 * Hamilton Depression score ≥7 points * Planned to undergo elective laparoscopic sleeve gastrectomy Exclusion Criteria: * ASA ≥ grade IV * Those who have had or are currently suffering from mental disorders other than anxiety and depression, such as schizophrenia, bipolar disorder, organic mental disorders, etc. * Those who are unable to cooperate in completing the scale assessment * Have received ketamine/esketamine treatment, or are allergic to ketamine/esketamine * Clarify ischemic cardiomyopathy or severe liver and kidney dysfunction (Child pugh grade C, CKD stage G5) * People with opioid dependence and those who have been taking various types of painkillers for a long time (more than 3 months) * Participate in other research

Where

1 study site

Facility	City	Region	Country
Zhiwen Li	Changchun	Jilin	China

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07179913 on ClinicalTrials.gov →

Last updated in the registry 2026-05-08. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Ketamine